Research & Development
Ironshore Pharmaceuticals Names Warrington to Head Medical Affairs
22 January 2019 - - US-based Attention Deficit Hyperactivity Disorder treatments provider Ironshore Pharmaceuticals, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., has appointed D...
OliX reports clinical candidate nomination of OLX10020 for Geographic Atrophy
21 January 2019 - RNAi therapeutics company OliX Pharmaceuticals Inc (Kosdaq:226950) said on Friday that it has nominated OLX10020 as the clinical candidate for the treatment of Geographic Atrophy (GA...
AbbVie updates on Phase three RESOLVE trial of ibrutinib
21 January 2019 - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced on Friday an update on the Phase three RESOLVE trial (PCYC-1137) of ibrutinib (IMBRUVICA) in combina...
Acrotech Biopharma to acquire seven FDA-approved haematology/oncology products from Spectrum Pharmaceuticals
21 January 2019 - Acrotech Biopharma, a subsidiary of Aurobindo Pharma, has agreed to acquire seven FDA-approved haematology/oncology products from Spectrum Pharmaceuticals, it was reported on Friday....
Omeros Finalises with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
18 January 2019 - - US-based commercial-stage biopharmaceutical company Omeros Corp. (NASDAQ: OMER) has finalised its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy f...
Spectrum Pharmaceuticals reports divestiture of marketed portfolio to focus on new and innovative therapies for cancer patients
18 January 2019 - Biotechnology company Spectrum Pharmaceuticals Inc (NASDAQ-GS:SPPI) revealed on Thursday the launch of a definitive agreement to divest its portfolio of seven products to Acrotech Bi...